Jpmorgan Chase & CO Clearside Biomedical, Inc. Put Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding CLSD
# of Institutions
55Shares Held
12.2MCall Options Held
54.7KPut Options Held
50.7K-
Vanguard Group Inc Valley Forge, PA2.84MShares$3.04 Million0.0% of portfolio
-
Act Capital Management, LLC Wayne, PA2.2MShares$2.35 Million3.43% of portfolio
-
Carmignac Gestion Paris, I01.93MShares$2.07 Million0.04% of portfolio
-
Black Rock Inc. New York, NY798KShares$854,0060.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny745KShares$797,0310.0% of portfolio
About Clearside Biomedical, Inc.
- Ticker CLSD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,190,700
- Market Cap $64.4M
- Description
- Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...